CORDIS
EU research results

CORDIS

English EN

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Project information

Grant agreement ID: 847782

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 9 996 350,25

  • EU contribution

    € 9 996 350,25

Coordinated by:

CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

France

Objective

“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases.
HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance.
The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.

Coordinator

CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

Address

Allee De L'Ile Gloriette 5
44093 Nantes

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 642 770,25

Participants (9)

UNIVERSITE DE NANTES

France

EU Contribution

€ 1 273 025

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA

Spain

EU Contribution

€ 841 365

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 1 510 587,50

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 96 081,25

UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN

United States

EU Contribution

€ 322 837,50

HOSPICES CIVILS DE LYON

France

EU Contribution

€ 315 227,50

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 785 000

NEUMEDICINES INC.

United States

EU Contribution

€ 732 127,50

BIG DATA SANTE

France

EU Contribution

€ 477 328,75

Project information

Grant agreement ID: 847782

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 9 996 350,25

  • EU contribution

    € 9 996 350,25

Coordinated by:

CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

France